<DOC>
	<DOC>NCT00434525</DOC>
	<brief_summary>- The investigators aim to determine the clinical and metabolic effects of sleeve gastrectomy with or without omentectomy in the treatment of morbid obesity. - The investigators hypothesize that the endocrine suppression of ghrelin (appetite hormone)and resistin (insulin antagonist) provided by sleeve gastrectomy and omentectomy (omentum or intra-abdominal fat removal) will provide clinical and metabolic benefits for morbidly obese patients.</brief_summary>
	<brief_title>Laparoscopic Sleeve Gastrectomy With and Without Omentectomy</brief_title>
	<detailed_description>This is a phase 3 prospective randomized trial.</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Obesity, Morbid</mesh_term>
	<criteria>Morbidly obese VETERANS ONLY (BMI&gt;35 with comorbidities or BMI&gt;40) Age &gt; 18 Pregnancy Uncontrolled medical or psychiatric conditions Previous bariatric procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Morbid obesity</keyword>
	<keyword>Bariatric Surgery</keyword>
	<keyword>Obesity Surgery</keyword>
	<keyword>Omentectomy</keyword>
	<keyword>Sleeve gastrectomy</keyword>
</DOC>